Amylyx Pharmaceuticals (AMLX) Net Margin (2021 - 2024)
Amylyx Pharmaceuticals (AMLX) posted Net Margin of 4011.01% for Q4 2024, up 77.05% on a QoQ basis from 17476.92% in Q3 2024, and down 401516.0% year-over-year from N/an in Q1 2024.
Powered by 
Analysis
Amylyx Pharmaceuticals (AMLX) Net Margin (2021 - 2024) Analysis & Trends
Amylyx Pharmaceuticals has reported Net Margin for 4 years, with the latest figure at 4011.01% in Q4 2024.
- On a quarterly basis, Net Margin fell 401516.0% year-over-year to 4011.01% in Q4 2024; TTM through Sep 2025 was 13557.55%, a 1368835.0% increase from a year earlier, with the FY2024 full-year figure at 273.1%, down 28598.0% from the prior year.
- Net Margin was 4011.01% for Q4 2024 at Amylyx Pharmaceuticals, up from 17476.92% in the prior quarter.
- The five-year high for Net Margin was 22.47% in Q2 2023, with the low at 17476.92% in Q3 2024.
- Average Net Margin over 4 years is 4780.08%, with a median of 200.15% recorded in 2022.
- The sharpest annual moves came in 2023 and 2024: Net Margin soared 1560179 bps in 2023, then tumbled 1749727 bps in 2024.
- Over 4 years, Net Margin stood at 8120.0% in 2021, then jumped by 98 bps to 200.15% in 2022, then soared by 102 bps to 4.16% in 2023, then sank by 96614 bps to 4011.01% in 2024.
- The last three Net Margin figures came in at 4011.01% (Q4 2024), 17476.92% (Q3 2024), and 7106.55% (Q2 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.88 Bn | 197.89 Bn | 7.24 Bn | 23.62% |
| 2 | Gilead Sciences | 181.55 Bn | 178.37 Bn | 6.22 Bn | -134.51% |
| 3 | Vertex Pharmaceuticals | 132.31 Bn | 124.45 Bn | 2.84 Bn | 32.99% |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn | 30.23% |
| 5 | Argenx Se | 61.54 Bn | 56.36 Bn | 1.37 Bn | 31.16% |
| 6 | Moderna | 54.69 Bn | 49.55 Bn | 52.00 Mn | -539.31% |
| 7 | Alnylam Pharmaceuticals | 34.07 Bn | 30.76 Bn | 992.69 Mn | 12.74% |
| 8 | Biogen | 31.41 Bn | 30.12 Bn | 1.96 Bn | 3.56% |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn | -20,152.98% |
| 10 | Amylyx Pharmaceuticals | 3.69 Bn | 3.69 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -4,011.01% |
| Sep 30, 2024 | -17,476.92% |
| Jun 30, 2024 | -7,106.55% |
| Mar 31, 2024 | -134.01% |
| Dec 31, 2023 | 4.16% |
| Sep 30, 2023 | 20.35% |
| Jun 30, 2023 | 22.47% |
| Mar 31, 2023 | 2.20% |
| Dec 31, 2022 | -200.15% |
| Sep 30, 2022 | -15,581.45% |
| Sep 30, 2021 | -8,120.00% |